Overwhelmed by the cannabis earnings reports? Here's the metric that Jim Cramer watches.
Plus, why investors should care about the yield curve, and a closer look at Tilray's quarter.
Tilray shares turn following the company's fourth-quarter results while other pot stocks trade mixed.
It might not be time to panic yet about Tilray, but there's likely a problem ahead.
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Investors looking for another hemp play might consider Charlotte's Web Holdings, which deals in a range of CBD wellness products.
A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.
Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.